Ziccum AB (publ) has received data from external contract research (CRO) partner Truly Labs, confirming high activity levels in mRNA/LNP materials dried by LaminarPace, after continued internal confirmations. The in-vitro data validate the ability of Ziccum's LaminarPace technology to transform delicate mRNA/LNP solution into stable, bioactive dry powder with excellent in-vitro characteristics. The external confirmation and extended data set of preserved mRNA activity after LaminarPace treatment was obtained with cell-based in-vitro assays by the CRO.

The study was performed to validate the internal mRNA activity data previously reported on March 20th. The new data give a clear and distinctive confirmation of the ability of Ziccum's LaminarPace technology to transform delicate mRNA/LNP solution into stable, bioactive dry powder with excellent in-vitro characteristics. mRNA is one of the three target vaccine platforms Ziccum focuses on, and its in-house mRNA project is of central strategic importance, considering the market need and growth.

In October 2022, Ziccum reported proof of successful nebulization and drying of a vaccine/LNP model substance. In March 2023, Ziccum reported the same positive confirmations regarding encapsulation and particle properties for actual mRNA/LNP trials, plus confirmed mRNA activity after LaminarPace drying and reconstitution to liquid. These findings have since then been repeatedly confirmed in continued internal studies.

The new CRO activity read-outs are obtained in a different mRNA model - and having the same clear activity preservation in a second mRNA model makes the validation stronger. Ziccum has recently signed two major agreements for Evaluation Studies on mRNA/LNP treatment with LaminarPace ­ the first in May with a leading Biopharmaceutical corporation, the second in July with a multinational Pharmaceutical corporation. These collaborations also will include in-vitro activity readouts.